$12.3 M

PTIX Mkt cap, 22-Sept-2020
Protagenic Therapeutics Net income (Q2, 2020)-567.4 K
Protagenic Therapeutics EBIT (Q2, 2020)-488.9 K
Protagenic Therapeutics Cash, 30-Jun-20201.2 M
Protagenic Therapeutics EV12.1 M

Protagenic Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

R&D expense

533.7k717.5k881.2k807.9k

General and administrative expense

491.0k1.3m1.6m1.4m1.3m

Operating expense total

491.0k1.8m2.4m2.3m2.1m

EBIT

(491.0k)(2.2m)(2.4m)(2.3m)(2.1m)

Interest expense

42.3k105.7k243.4k

Interest income

8.0k2.8k

Pre tax profit

(501.0k)(2.3m)(2.3m)(2.6m)(1.8m)

Income tax expense

Net Income

(1.1m)(476.0k)(2.3m)(2.3m)(2.6m)(1.8m)

Protagenic Therapeutics Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

2.3m2.0m111.0k150.0k57.0k10.0k4.0k3.8m3.8m3.5m2.7m627.8k952.1k343.3k236.0k431.9k419.3k339.5k277.4k754.0k1.2m

Accounts Receivable

4.1m5.3m

Prepaid Expenses

1.0m900.0k134.0k110.0k89.0k49.0k21.0k96.7k24.2k114.8k42.3k6.0k64.0k44.9k9.8k9.5k31.7k6.5k

Current Assets

8.6m9.1m245.0k260.0k146.0k59.0k25.0k3.8m3.8m3.6m2.8m2.5m2.2m1.5m1.1m989.7k464.2k349.3k286.9k785.7k1.2m

PP&E

2.4m2.5m1.0k1.0k2.0k1.0k1.0k1.6k215.01.2k1.1k908.0805.0732.0540.0463.0374.0191.0117.0

Total Assets

15.0m14.1m246.0k261.0k148.0k60.0k26.0k3.8m3.8m3.6m2.8m2.5m2.2m1.5m1.1m990.5k464.8k349.8k287.3k785.8k1.2m

Accounts Payable

2.8m5.2m164.0k164.0k172.0k174.0k192.0k172.7k87.3k131.6k75.8k73.8k101.6k84.5k124.9k259.3k199.9k329.1k316.1k552.8k504.9k

Short-term debt

2.9m3.0m265.0k415.0k415.0k565.0k665.0k

Current Liabilities

15.2m18.8m435.0k589.0k602.0k767.0k892.0k736.0k603.1k648.3k592.8k578.1k536.9k504.1k532.5k667.4k826.6k729.2k651.0k824.2k799.9k

Long-term debt

433.6k960.7k

Total Debt

2.9m3.0m265.0k415.0k415.0k565.0k665.0k433.6k960.7k

Total Liabilities

16.1m19.7m435.0k589.0k602.0k767.0k892.0k1.4m1.9m

Common Stock

70.0k70.0k400.09.0831.01.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k

Preferred Stock

5.0k5.0k5.0k5.0k5.0k

Additional Paid-in Capital

181.4m181.5m1.1m1.1m1.1m1.1m1.1m10.2m10.9m11.1m11.6m11.7m12.0m12.6m12.8m13.1m13.8m14.1m14.2m15.2m15.6m

Retained Earnings

(177.7m)(182.2m)(1.2m)(1.3m)(1.4m)(1.7m)(1.8m)(7.0m)(7.6m)(8.0m)(9.2m)(9.7m)(10.1m)(11.4m)(12.1m)(12.6m)(14.0m)(14.3m)(14.4m)(15.6m)(16.2m)

Total Equity

(1.1m)(5.7m)(189.0k)(328.0k)(454.0k)(707.0k)(866.0k)3.0m3.2m2.9m2.2m1.9m1.7m964.9k559.9k323.0k(361.8k)(379.5k)(363.7k)(585.9k)(746.1k)

Financial Leverage

-13.5 x-2.5 x-1.3 x-0.8 x-0.3 x-0.1 x0 x1.2 x1.2 x1.2 x1.3 x1.3 x1.3 x1.5 x2 x3.1 x-1.3 x-0.9 x-0.8 x-1.3 x-1.6 x

Protagenic Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(1.1m)(476.0k)(2.3m)(2.3m)(2.6m)(1.8m)

Depreciation and Amortization

1.0k534.0148.0347.0339.0

Accounts Receivable

6.2k

Accounts Payable

(33.0k)30.0k98.6k662.2k

Cash From Operating Activities

(790.0k)(378.0k)(1.1m)(1.4m)(1.1m)(488.0k)

Purchases of PP&E

(1.0k)(1.0k)

Cash From Investing Activities

(1.0k)(1.0k)(1.3m)1.0m250.0k

Cash From Financing Activities

175.0k340.0k4.3m670.0k

Net Change in Cash

(616.0k)(39.0k)3.1m(2.7m)(37.2k)436.1k

Interest Paid

Income Taxes Paid

Protagenic Therapeutics Ratios

USDQ2, 2011

Financial Leverage

-13.5 x